JP2014076062A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014076062A5 JP2014076062A5 JP2013268626A JP2013268626A JP2014076062A5 JP 2014076062 A5 JP2014076062 A5 JP 2014076062A5 JP 2013268626 A JP2013268626 A JP 2013268626A JP 2013268626 A JP2013268626 A JP 2013268626A JP 2014076062 A5 JP2014076062 A5 JP 2014076062A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- heavy chain
- pharmaceutical composition
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37448910P | 2010-08-17 | 2010-08-17 | |
US61/374,489 | 2010-08-17 | ||
PCT/AU2011/000155 WO2011100786A1 (en) | 2010-02-17 | 2011-02-17 | Compositions and methods for targeting type 1 interferon producing cells |
AUPCT/AU2011/000155 | 2011-02-17 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013524306A Division JP5524418B2 (ja) | 2010-08-17 | 2011-08-17 | ヒト化抗インターロイキン3レセプターα鎖抗体 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014076062A JP2014076062A (ja) | 2014-05-01 |
JP2014076062A5 true JP2014076062A5 (US07794700-20100914-C00152.png) | 2014-09-18 |
JP5933517B2 JP5933517B2 (ja) | 2016-06-08 |
Family
ID=45604615
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013524306A Active JP5524418B2 (ja) | 2010-08-17 | 2011-08-17 | ヒト化抗インターロイキン3レセプターα鎖抗体 |
JP2013268626A Active JP5933517B2 (ja) | 2010-08-17 | 2013-12-26 | ヒト化抗インターロイキン3レセプターα鎖抗体 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013524306A Active JP5524418B2 (ja) | 2010-08-17 | 2011-08-17 | ヒト化抗インターロイキン3レセプターα鎖抗体 |
Country Status (13)
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102089004B (zh) * | 2008-07-10 | 2018-06-01 | 东丽株式会社 | 癌的治疗及预防用药物组合物 |
US20100209341A1 (en) | 2009-02-18 | 2010-08-19 | Csl Limited | Treatment of chronic inflammatory conditions |
WO2010126066A1 (ja) | 2009-04-27 | 2010-11-04 | 協和発酵キリン株式会社 | 血液腫瘍治療を目的とした抗IL-3Rα抗体 |
NZ604510A (en) | 2010-08-17 | 2013-10-25 | Csl Ltd | Dilutable biocidal compositions and methods of use |
ES2924722T3 (es) * | 2012-05-18 | 2022-10-10 | Aptevo Res & Development Llc | Unión de inmunofusión de scFv biespecífico (BIf) a CD123 y CD3 |
WO2014138805A1 (en) * | 2013-03-14 | 2014-09-18 | Csl Limited | Anti il-3r alpha agents and uses thereof |
WO2014138819A1 (en) * | 2013-03-14 | 2014-09-18 | Csl Limited | Agents that neutralize il-3 signaling and uses thereof |
EP2839842A1 (en) * | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
ME03724B (me) * | 2014-09-05 | 2021-01-20 | Janssen Pharmaceutica Nv | Agensi koji vezuju cd123 i njihove upotrebe |
AU2016210068B2 (en) | 2015-01-23 | 2021-10-28 | Sanofi | Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123 |
TW201709932A (zh) * | 2015-06-12 | 2017-03-16 | 西雅圖遺傳學公司 | Cd123抗體及其共軛物 |
CA2990398A1 (en) * | 2015-06-23 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-cd123-antibodies |
BR112017027254A2 (pt) * | 2015-06-29 | 2019-05-14 | Immunogen, Inc. | anticorpos anti-cd123 e conjugados e derivados dos mesmos |
AU2017236431A1 (en) | 2016-03-24 | 2018-09-27 | Bayer Pharma Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
CA3027445A1 (en) | 2016-06-15 | 2017-12-21 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
WO2018057802A1 (en) * | 2016-09-21 | 2018-03-29 | Aptevo Research And Development Llc | Cd123 binding proteins and related compositions and methods |
JP7174704B2 (ja) | 2016-12-21 | 2022-11-17 | バイエル・アクチエンゲゼルシヤフト | 酵素開裂基を有する細胞毒性活性剤のプロドラッグ |
EP3558387B1 (de) | 2016-12-21 | 2021-10-20 | Bayer Pharma Aktiengesellschaft | Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren |
KR102556826B1 (ko) | 2016-12-21 | 2023-07-18 | 바이엘 파마 악티엔게젤샤프트 | 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc) |
PE20191846A1 (es) | 2017-06-02 | 2019-12-31 | Pfizer | Anticuerpos especificos para flt3 y sus usos |
US20200360531A1 (en) | 2018-01-31 | 2020-11-19 | Bayer Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
EP3966242A1 (en) | 2019-05-04 | 2022-03-16 | Inhibrx, Inc. | Cd123-binding polypeptides and uses thereof |
WO2021013693A1 (en) | 2019-07-23 | 2021-01-28 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
MX2023007901A (es) | 2020-12-31 | 2023-07-11 | Sanofi Sa | Acopladores de celulas asesinas naturales (nk) multifuncionales que se unen a nkp46 y a cd123. |
WO2023012367A1 (en) * | 2021-08-06 | 2023-02-09 | Universität Basel | Discernible cell surface protein variants for use in cell therapy |
EP4296280A1 (en) | 2022-06-21 | 2023-12-27 | F. Hoffmann-La Roche AG | Cd123 and cd200 as markers for the diagnosis and immune-eradication of leukemic stem cells (lscs) |
WO2024105206A1 (en) | 2022-11-17 | 2024-05-23 | Vincerx Pharma Gmbh | Antibody-drug-conjugates cleavable in a tumor microenvironment |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
WO1994007921A1 (en) | 1992-09-25 | 1994-04-14 | Commonwealth Scientific And Industrial Research Organisation | Target binding polypeptide |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
US6177078B1 (en) * | 1995-12-29 | 2001-01-23 | Medvet Science Pty Limited | Monoclonal antibody antagonists to IL-3 |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
WO1999054342A1 (en) | 1998-04-20 | 1999-10-28 | Pablo Umana | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
US6489447B1 (en) | 1998-05-06 | 2002-12-03 | Genentech, Inc. | Protein purification |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
ES2420835T3 (es) | 1999-04-09 | 2013-08-27 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de las moléculas inmunofuncionales |
US7229619B1 (en) | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20080260731A1 (en) | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
TR201809892T4 (tr) | 2003-11-05 | 2018-07-23 | Roche Glycart Ag | Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller. |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
KR100627856B1 (ko) * | 2004-06-28 | 2006-09-25 | 에스케이 텔레콤주식회사 | 착신측 교환기를 이용하여 멀티미디어 링백톤 서비스를제공하는 방법 및 시스템 |
RU2412200C2 (ru) * | 2004-11-12 | 2011-02-20 | Ксенкор, Инк. | Fc-ВАРИАНТЫ С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ С FcRn |
US20070135620A1 (en) | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US20080206239A1 (en) | 2005-02-03 | 2008-08-28 | Antitope Limited | Human Antibodies And Proteins |
US20060263367A1 (en) | 2005-05-23 | 2006-11-23 | Fey Georg H | Bispecific antibody devoid of Fc region and method of treatment using same |
CA2619244A1 (en) | 2005-08-15 | 2007-02-22 | Arana Therapeutics Limited | Engineered antibodies with new world primate framework regions |
EP2064240A2 (en) | 2006-09-18 | 2009-06-03 | Xencor, Inc. | Optimized antibodies that target hm1.24 |
EP1985305A1 (en) | 2007-04-24 | 2008-10-29 | Vivalis | Duck embryonic derived stem cell lines for the production of viral vaccines |
EP1995309A1 (en) | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
AU2008331436A1 (en) * | 2007-12-06 | 2009-06-11 | Csl Limited | Method of inhibition of leukemic stem cells |
US8313942B2 (en) * | 2008-09-26 | 2012-11-20 | Wyeth Llc | Compatible display vector systems |
US20100209341A1 (en) * | 2009-02-18 | 2010-08-19 | Csl Limited | Treatment of chronic inflammatory conditions |
WO2010126066A1 (ja) | 2009-04-27 | 2010-11-04 | 協和発酵キリン株式会社 | 血液腫瘍治療を目的とした抗IL-3Rα抗体 |
NZ604510A (en) | 2010-08-17 | 2013-10-25 | Csl Ltd | Dilutable biocidal compositions and methods of use |
-
2011
- 2011-06-07 NZ NZ604510A patent/NZ604510A/xx unknown
- 2011-08-17 CN CN201180036658.2A patent/CN103025761B/zh active Active
- 2011-08-17 ES ES11817577.7T patent/ES2506340T3/es active Active
- 2011-08-17 JP JP2013524306A patent/JP5524418B2/ja active Active
- 2011-08-17 EP EP11817577.7A patent/EP2606069B1/en active Active
- 2011-08-17 WO PCT/AU2011/001056 patent/WO2012021934A1/en active Application Filing
- 2011-08-17 GB GB1211289.2A patent/GB2488091B/en active Active
- 2011-08-17 PL PL11817577T patent/PL2606069T3/pl unknown
- 2011-08-17 EP EP14165984.7A patent/EP2778175B1/en active Active
- 2011-08-17 KR KR1020137002451A patent/KR101347688B1/ko active IP Right Grant
- 2011-08-17 US US13/256,926 patent/US8569461B2/en active Active
- 2011-08-17 DK DK11817577.7T patent/DK2606069T3/da active
- 2011-08-17 CA CA2805176A patent/CA2805176C/en active Active
-
2013
- 2013-04-08 IL IL225631A patent/IL225631A/en active IP Right Grant
- 2013-09-24 US US14/035,805 patent/US20140086912A1/en not_active Abandoned
- 2013-12-26 JP JP2013268626A patent/JP5933517B2/ja active Active
-
2015
- 2015-04-03 US US14/678,356 patent/US10047161B2/en active Active